Abstract 548P
Background
Lung cancer is the malignant tumor with the highest incidence rate and mortality in the world. The main types of lung cancer are nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With targeted therapy and immunotherapy emerging, treating NSCLC has made a great progress. However, the molecular mechanisms underlying progression of NSCLC remain elusive.
Methods
Completing gain- and loss-of-function experiments to view whether B-Myb regulates the function of lung cancer cells by targeting IGFBP3 in lung cancer cell lines H1299 and A549, respectively. Mechanistically, Using a stable strain of B-Myb lung cancer to build the animal model and collecting mouse blood to lymphocyte subgroup analysis by flow cytometry. Analyzing metabolic products of lung cancer by metabolomics.
Results
B-Myb increased in lung cancer tissues and cells notably, its expression interrelated with clinical stage and poor prognosis of patients with NSCLC. B-Myb may affect the proliferation, invasion, and migration of NSCLC by regulating IGFBP3. Importantly, overexpressing of B-Myb in NSCLC affects the expression of immune checkpoint PD-1/PD-L1 and lung cancer cell metabolism.
Conclusions
Our findings reveal that B-Myb may interact with IGFBP3 to promote the occurrence and development of NSCLC and affect immune checkpoints PD-1/PD-L1 expressing. B-Myb may become a potential new target for the diagnosis and treatment of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chongqing Municipal Education Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract